WeTrials
Recruiting

Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

What is this study?

This study is testing new combinations of immune-boosting drugs and chemotherapy for people with advanced lung cancer. It aims to help patients whose cancer has stopped responding to standard immunotherapy treatments.

Who can participate?

You may be able to join if you are 18 or older, have advanced non-small cell lung cancer that stopped responding to previous treatments, and meet specific health guidelines. People with certain severe immune system diseases or active infections cannot participate.

What will happen?

Participants will be randomly placed into groups to receive either the experimental drug combination or standard chemotherapy alone. Your health will be closely monitored by the study team throughout the process.

Where and when?

The study is currently recruiting participants at multiple locations, including sites in Arkansas and California, United States.

Key Points
  • 1Tests new drug combinations for advanced lung cancer
  • 2Designed for patients who need new options after standard treatments stopped working
  • 3Currently active and recruiting participants at specific medical centers

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
NSCLC Stage IV

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.